Latest posts
-
BioStem Technologies Reports Third Quarter 2023 Operating and Financial Results
Company to Host a Conference Call and Webcast on November 14, 2023, at 10:30 am EDT POMPANO BEACH, FLORIDA, November 13, 2023 – BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics, today reported financial results for the quarter ended September 30, 2023. Jason Matuszewski,
-
BioStem Technologies to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023
POMPANO BEACH, FLORIDA, November 6, 2023 – BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, announced today that it plans to release its third quarter 2023 financial results pre-market on Tuesday, November 14, 2023. BioStem will host a
-
BioStem Technologies Closes Oversubscribed $2M Private Placement
POMPANO BEACH, FLORIDA, November 3, 2023 – BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, today announces that it has closed an oversubscribed private placement of common stock to accredited investors for an aggregate of 1,337,000 units (each,
-
BioStem Technologies Announces Opening of First Clinical Site for Diabetic Foot Ulcer Study
Study to support differentiated efficacy of Vendaje® structural tissue allograft POMPANO BEACH, FLORIDA, October 24, 2023 – BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, today announced that the first site is now fully opened for its clinical
-
BioStem Technologies to Present at the Fall Foliage MicroCap Rodeo Conference
POMPANO BEACH, FLORIDA, October 18, 2023 – BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, will present at the 2023 virtual Fall Foliage MicroCap Rodeo Conference to be held from October 24th – 27th. Jason Matuszewski, Chief Executive
-
BioStem Technologies to Highlight Core Advanced Wound Care Portfolio at SAWC Fall 2023 Conference
POMPANO BEACH, FLORIDA, October 17, 2023 – BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announced that it will highlight the advantages of its Vendaje® and AmnioWrap2TM portfolios to help patients with difficult to heal chronic wounds at
-
BioStem Technologies: CMS Decision a “Win For Patients”
POMPANO BEACH, FLORIDA, September 29, 2023 – BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, today hails a decision by the Centers for Medicare & Medicaid Services (CMS) as being in the best interests of patients. Three Medicare
-
“We have already demonstrated scientifically that our process and product is exceptional.” Jason Matuszewski, Chief Executive Officer September 26, 2023 BioStem Technologies (OTC: BSEM) has received Investigational Review Board (IRB) approval for a clinical study that will investigate the utilization and effects of its Vendaje Ⓡ wound care product in diabetic foot ulcers. “We have
-
BioStem Technologies Takes on Diabetic Foot Ulcers with Innovative Wound Care Product
“We have already demonstrated scientifically that our process and product is exceptional.” Jason Matuszewski, Chief Executive Officer September 26, 2023 BioStem Technologies (OTC: BSEM) has received Investigational Review Board (IRB) approval for a clinical study that will investigate the utilization and effects of its Vendaje Ⓡ wound care product in diabetic foot ulcers. “We have already
-
BioStem Receives IRB Approval for Clinical Study to Evaluate Vendaje® in Diabetic Foot Ulcers
POMPANO BEACH, FLORIDA, September 26, 2023 – BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, announced today the approval of an Investigational Review Board (IRB) sanctioned clinical study. This study aims to investigate the utilization and effects of